Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-VC neoadjuvant vemurafenib + cobimetinib + atezolizumab in limited metastatic melanoma
2013-001546-34Phase 2Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib, cobimetinib and atezolizumab in melanoma, sponsored by University Hospital Tübingen. Primary endpoint: Operability after neoadjuvant treatment. Started Jul 2014; status: terminated.
02
Drugs
vemurafenibcobimetinibatezolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2013-001546-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001546-34.